常铝股份(002160) - 2020 Q4 - 年度财报

Financial Performance - The company's operating revenue for 2020 was ¥4,376,851,245.18, representing a 1.07% increase compared to ¥4,330,649,784.47 in 2019[19]. - The net profit attributable to shareholders for 2020 was ¥22,151,170.45, a 0.78% increase from ¥21,980,735.15 in 2019[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥1,220,142.89, a decrease of 108.86% compared to ¥13,768,323.22 in 2019[19]. - The net cash flow from operating activities decreased by 30.20% to ¥187,794,984.50 from ¥269,038,872.58 in 2019[19]. - Total assets at the end of 2020 were ¥6,507,582,475.31, an increase of 8.43% from ¥6,001,705,834.60 at the end of 2019[20]. - The net assets attributable to shareholders at the end of 2020 were ¥3,053,765,659.26, a 0.91% increase from ¥3,026,165,804.48 at the end of 2019[20]. - The company achieved a consolidated revenue of CNY 4.38 billion in 2020, representing a year-on-year growth of 1.07%[37]. - The net profit attributable to shareholders was CNY 22.15 million, an increase of 0.78% compared to the previous year[37]. - The cash flow from operating activities decreased by 30.20% year-on-year, amounting to CNY 187.80 million[37]. - The company reported a total revenue of 1.5 billion RMB for the year 2020, reflecting a year-on-year growth of 10%[92]. Dividend Policy - The company plans not to distribute cash dividends or issue bonus shares for the year[6]. - The company did not declare any cash dividends for 2020, 2019, or 2018, maintaining a cash dividend payout ratio of 0% for these years[88]. - The company has adhered to its cash dividend policy, which aligns with its articles of association and shareholder resolutions[84]. - The company has not proposed any capital reserve conversion into share capital for 2020 due to negative distributable profits[87]. Business Diversification and Strategy - The acquisition of Langmai Co. has diversified the company's operations into the pharmaceutical clean technology sector, reducing dependency on aluminum processing[5]. - The company’s main business has evolved to include pharmaceutical manufacturing and medical device production alongside aluminum products[17]. - The company is focusing on optimizing product structure and enhancing the value-added of materials through deep processing and innovation[29]. - The company is expanding its industrial layout with subsidiaries dedicated to raw material supply and further processing to meet customer demands in the air conditioning and automotive sectors[30]. - The company aims to enhance its market presence in new materials and products while ensuring operational stability amid market uncertainties[39]. - The company plans to adjust its product structure and strengthen its position in the industrial heat transfer sector while expanding into the automotive market[39]. - The company aims to enhance competitiveness and promote sustainable development through its dual business strategy of "Aluminum Processing + Health" moving forward[81]. Risk Management - The company reported a significant reliance on the aluminum rolling processing business, which is sensitive to macroeconomic changes and commodity price fluctuations[4]. - The company faces risks related to rising labor costs and the need for efficiency improvements through mechanization and standardization[5]. - The company’s overall risk management has improved due to the lower cyclical risks associated with the pharmaceutical industry[5]. Corporate Governance - The company’s financial report is guaranteed to be true, accurate, and complete by its management team[3]. - The company has established a comprehensive corporate governance structure and internal control system to ensure fair and transparent communication with all shareholders, enhancing transparency and credibility[124]. - The company has maintained compliance with decision-making procedures regarding dividend distribution and has ensured the protection of minority shareholders' rights[84]. - The company has no significant discrepancies with the regulatory requirements set by the China Securities Regulatory Commission regarding corporate governance[172]. Shareholder Information - The company has not reported any changes in its controlling shareholder since its listing[17]. - The company’s controlling shareholder, Changshu Aluminum Foil Factory Co., Ltd., has not undergone any changes during the reporting period[143]. - The largest shareholder, Changshu Aluminum Foil Factory Co., Ltd., holds 20.33% of the shares, totaling 161,742,997 shares, with a decrease of 2,371,492 shares during the reporting period[140]. - The company has a total of 78,931 shareholders at the end of the reporting period, with no changes in the structure of assets and liabilities reported[138]. Employee and Labor Relations - The total number of employees in the company is 2,243, with 1,536 in production, 117 in sales, 297 in technical roles, 95 in finance, and 198 in administration[164]. - The company has established a comprehensive training system for employees, including onboarding and ongoing training[167]. - The total compensation for directors and senior management during the reporting period amounts to 426.54 million yuan[164]. - The company has not implemented any employee incentive plans during the reporting period[104]. Audit and Compliance - The company received a standard unqualified audit report from the accounting firm for the 2020 financial statements[181]. - The audit committee held seven meetings during the reporting period, ensuring the legality and compliance of the company's fundraising and usage[180]. - There were no significant internal control deficiencies identified during the reporting period[186]. - The auditor evaluates the appropriateness of accounting policies and the reasonableness of accounting estimates and related disclosures made by management[200].